Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
AssigneeUniversity of Notre Dame du Lac
InventorSteven Buechler
Life of this patent
Estimating the term…
Abstract
Products, systems, and methods for classifying human colorectal cancer into a consensus molecular subtype (CMS) and for assessing risk of recurrence based on CMS scores and based on risk scores derived from abbreviated gene expression profiles, for determining suitable treatment protocols for human colorectal cancer patients based on the determined CMS classification and based on the determined risk of recurrence, and for administering the suitable treatment protocols.
Claims27
1-26. (canceled)
A method of accurately determining a consensus molecular subtype of a colorectal cancer from a cancer patient, the method comprising:
- obtaining an expression level of at least three colorectal cancer RNA transcripts from a first group of genetic elements, the first group of genetic elements comprising genes ENTREZ IDs 6418, 9219, 10855, 3191, 9037, 10079, 83737, 10140, 8313, 54891, 57798, 998, 7105, 23475, 6431, 3725, 81786, 9554, 1602, 57168, 401474, 139322, 1783, 29966, 80183, 8019, 3549, 27330, and 10451;
- obtaining an expression level of at least three colorectal cancer RNA transcripts from a second group of genetic elements, the second group of genetic elements comprising genes ENTREZ IDs 5326, 112858, 1057, 6780, 23509, 51497, 430, 171023, 25980, 23475, 22919, 80183, 51526, 28951, 1056, 1846, 644, 9054, 55661, 54894, 58490, and 4212;
- obtaining an expression level of at least three colorectal cancer RNA transcripts from a third group of genetic elements, the third group of genetic elements comprising genes 4217, 84666, 8857, 7078, 80150, 4151, 54596, 143458, 84189, 7410, 5937, 25837, 10753, 192134, 201501, 9509, 140828, 84624, 1290, 405753, 1278, 2335, 1295, 3488, 9254, and 155465;
- obtaining an expression level of at least three colorectal cancer RNA transcripts from a fourth group of genetic elements, the fourth group of genetic elements comprising genes ENTREZ IDs 23414, 30008, 27295, 2737, 143903, 154810, 11037, 7145, 9590, 5178, 23194, 4256, 10000, 1410, 862, 4286, 83871, 421 1, 165, 6695, 1292, 9353, 4131, 8639, 5549, 547%, 147906, and 8828;
- determining, based on the expression level of each of the at least three RNA transcripts from the first group of genetic elements, a first CMS score representative of a probability that the CMS of the colorectal cancer is CMS1;
- determining, based on the expression level of each of the at least three RNA transcripts from the second group of genetic elements, a second CMS score representative of a probability that the CMS of the colorectal cancer is CMS2;
- determining, based on the expression level of each of the at least three RNA transcripts from the third group of genetic elements, a third CMS score representative of a probability that the CMS of the colorectal cancer is CMS3;
- determining, based on the expression level of each of the at least three RNA transcripts from the fourth group of genetic elements, a fourth CMS score representative of a probability that the CMS of the colorectal cancer is CMS4;
- and
- generating a report indicating one or more of:
- the first, second, third, and/or fourth CMS scores;
- the probability that the CMS of the colorectal cancer is CMS1, CMS2, CMS3, and/or CMS4;
- and
- a treatment protocol specific for the colorectal cancer, wherein one or more of the first, second, third, and/or fourth CMS scores, and the probability that the CMS of the colorectal cancer is CMS1, CMS2, CMS3, and/or CMS4 indicates the treatment protocol specific for the colorectal cancer.
(canceled)
(canceled)
41-44. (canceled)
A method of classifying a human colorectal cancer tumor into a consensus molecular subtype (CMS) based on a CMS score derived from an abbreviated gene expression profile, the method comprising:
- obtaining an expression level of at least three RNA transcripts from a colorectal cancer tissue sample, the at least three RNA transcripts being selected from a first group of genetic elements that define a first CMS profile for one of CMS1, CMS2, CMS3, and CMS4;
- determining, based on the expression level of each of the at least three RNA transcripts from the first group of genetic elements, a first CMS score representative of a probability that the CMS of the colorectal cancer corresponds with the CMS of the first CMS profile;
- and
- classifying the colorectal cancer with a CMS determination corresponding to the CMS of the first CMS profile based at least in part on the first CMS score, wherein the first CMS score is above a predictive threshold.
49-56. (canceled)
(canceled)
(canceled)
62-112. (canceled)
Dependencies are inferred from the claim text.